The Patented Medicine Prices Review Board (PMPRB) has advised that the new Guidelines will not be implemented on January 1, 2023, and that the Interim Guidance issued by the Board on August 18, 2022 will remain in place until further notice. The comment period on the proposed Guidelines closed on December 5, 2022 (see our article on the draft Guidelines). 88 submissions were provided (see “Submissions” tab), including from Health Canada. Health Canada asked PMPRB to consider pausing the consultation process, reasoning that “[a] pause will allow time to work collaboratively, with all stakeholders and health system partners, to understand fully the short and long-term impacts of the proposed new Guidelines.”
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
CADTH time-limited recommendation category to enhance earlier access to promising new drugs
On September 28, 2023, the Canadian Agency for Drugs and Technologies in Health introduced the time-limited reimbursement recommendation category, which aims to provide early access to promising new d...Read More -
PMPRB news: Upcoming roundtable as first phase of new guidelines consultation, two new appointments
On October 25, 2023, the Patented Medicine Prices Review Board (PMPRB) announced that it will launch the first phase of consultations on new guidelines.Read More -
PMPRB publishes scoping paper for consultation on guidelines and invites stakeholder feedback
The Patented Medicine Prices Review Board announced that it will launch the first phase of consultations on new guidelines. On November 10, 2023, the PMPRB published its Scoping Paper for the Consulta...Read More